US6043057A
(en)
*
|
1988-09-16 |
2000-03-28 |
Vitec Aktiebolag |
Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
|
IT1253009B
(it)
*
|
1991-12-31 |
1995-07-10 |
Sclavo Ricerca S R L |
Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
|
GB9513371D0
(en)
|
1995-06-30 |
1995-09-06 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
US6436407B1
(en)
|
1994-08-26 |
2002-08-20 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic adjuvant
|
US6019982A
(en)
*
|
1994-08-26 |
2000-02-01 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic oral adjuvant
|
GB9603314D0
(en)
*
|
1996-02-16 |
1996-04-17 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
GB9622660D0
(en)
|
1996-10-31 |
1997-01-08 |
Biocine Spa |
Immunogenic detoxified mutant toxin
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
US6030619A
(en)
|
1997-08-27 |
2000-02-29 |
Chiron Corporation |
Molecular mimetics of meningococcal B epitopes
|
AU3089599A
(en)
*
|
1998-03-18 |
1999-10-11 |
Smithkline Beecham Corporation |
Production of purified mutant enterotoxin for use as an adjuvant
|
US6033673A
(en)
*
|
1998-03-18 |
2000-03-07 |
The Administrators Of Tulane Educational Fund |
Double mutant enterotoxin for use as an adjuvant
|
AU761780B2
(en)
|
1998-05-01 |
2003-06-12 |
Glaxosmithkline Biologicals Sa |
Neisseria meningitidis antigens and compositions
|
CA2335487A1
(en)
|
1998-06-19 |
1999-12-23 |
Merieux Oravax |
Lt and ct in parenteral immunization methods against helicobacter infection
|
EP1117435B1
(de)
*
|
1998-09-30 |
2007-11-14 |
Wyeth Holdings Corporation |
Mutiertes cholera holotoxin als hilfsmittel
|
JP2002533068A
(ja)
*
|
1998-12-22 |
2002-10-08 |
ボイス トンプソン インスティテュート フォア プラント リサーチ |
トランスジェニック植物に発現される経口で免疫原性の細菌エンテロトキシン
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
JP2002533124A
(ja)
|
1998-12-31 |
2002-10-08 |
カイロン コーポレイション |
Hivポリペプチドの改善された発現およびウイルス様粒子の生成
|
WO2000050078A1
(en)
|
1999-02-26 |
2000-08-31 |
Chiron Corporation |
Use of bioadhesives and adjuvants for the mucosal delivery of antigens
|
EP2286792A1
(de)
|
1999-02-26 |
2011-02-23 |
Novartis Vaccines and Diagnostics, Inc. |
Mikroemulsionen mit einer adsorbierenden Oberfläche, enthaltend eine Mikrotropfenemulsion
|
US7115730B1
(en)
|
1999-04-27 |
2006-10-03 |
Chiron Srl |
Immunogenic detoxified mutant E. coli LT-A-toxin
|
US7384640B1
(en)
|
1999-09-30 |
2008-06-10 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant
|
AU2001247522A1
(en)
*
|
2000-03-17 |
2001-10-03 |
Uab Research Foundation |
Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediatedor humoral immunity
|
WO2001089456A2
(en)
|
2000-05-19 |
2001-11-29 |
The Administrators Of The Tulane Educational Fund |
Hybrid lt-a/ct-b holotoxin for use as an adjuvant
|
ATE493495T1
(de)
*
|
2000-09-08 |
2011-01-15 |
Univ Maryland Biotech Inst |
Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen
|
US20030162733A1
(en)
*
|
2000-11-27 |
2003-08-28 |
Haynes Joel R. |
Nucleic acid adjuvants
|
WO2002080982A2
(en)
|
2001-01-12 |
2002-10-17 |
Chiron Corporation |
Nucleic acid mucosal immunization
|
US7384775B2
(en)
|
2001-04-16 |
2008-06-10 |
Wyeth |
Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
|
US7285281B2
(en)
|
2001-06-07 |
2007-10-23 |
Wyeth Holdings Corporation |
Mutant forms of cholera holotoxin as an adjuvant
|
JP2005508143A
(ja)
*
|
2001-06-07 |
2005-03-31 |
ワイス・ホールデイングス・コーポレーシヨン |
アジュバントとしてのコレラホロトキシンの突然変異形
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
EP1411770A4
(de)
|
2001-07-05 |
2006-05-10 |
Chiron Corp |
Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
|
CA2452119C
(en)
|
2001-07-05 |
2013-10-15 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
US7501134B2
(en)
|
2002-02-20 |
2009-03-10 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
CA2479118A1
(en)
|
2002-03-15 |
2003-09-25 |
Wyeth Holdings Corporation |
Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
CN101721697A
(zh)
|
2002-10-01 |
2010-06-09 |
诺华疫苗和诊断公司 |
抗癌及抗感染性疾病组合物及其使用方法
|
EP1585542B1
(de)
|
2002-12-27 |
2012-06-13 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogene zusammensetzungen enthaltend phospholipid
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
ATE437633T2
(de)
|
2003-06-02 |
2009-08-15 |
Novartis Vaccines & Diagnostic |
Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
|
WO2005020902A2
(en)
|
2003-08-21 |
2005-03-10 |
Cytokine Pharmasciences, Inc. |
Compositions and methods for treating and diagnosing irritable bowel syndrome
|
GB0325494D0
(en)
*
|
2003-10-31 |
2003-12-03 |
Sbl Vaccin Ab |
Expression system
|
UA93854C2
(ru)
|
2003-12-17 |
2011-03-25 |
Вайет Ллк |
Иммуногенный конъюгат и способ его получения
|
CN1934127B
(zh)
|
2003-12-17 |
2015-08-19 |
杨森阿尔茨海默氏症免疫治疗公司 |
Αβ免疫原性肽载体-偶联物及其生产方法
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
JP2008502363A
(ja)
|
2004-05-21 |
2008-01-31 |
ワイス |
Staphylococcusaureusの改変型フィブロネクチン結合タンパク質
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
AU2005333603A1
(en)
|
2004-10-21 |
2007-01-04 |
Wyeth |
Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
|
WO2006050394A2
(en)
|
2004-11-01 |
2006-05-11 |
Novartis Vaccines And Diagnostics Inc. |
Combination approaches for generating immune responses
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
CN101180079B
(zh)
|
2005-04-08 |
2012-07-18 |
惠氏公司 |
多价肺炎球菌多糖-蛋白质缀合物组合物
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
US8926993B2
(en)
|
2006-07-17 |
2015-01-06 |
Aduro Biotech |
Methods and compositions using Listeria for enhancing immunogenicity by prime boost
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
WO2010027818A2
(en)
|
2008-08-25 |
2010-03-11 |
Dana-Farber Cancer Institute, Inc. |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
JP5722782B2
(ja)
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
DK2356135T3
(en)
|
2008-11-05 |
2017-12-04 |
Wyeth Llc |
IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE
|
AU2009314091B2
(en)
|
2008-11-12 |
2015-05-14 |
Theraclone Sciences, Inc. |
Human M2e peptide immunogens
|
US8425922B2
(en)
|
2009-01-05 |
2013-04-23 |
EpitoGenesis, Inc. |
Adjuvant compositions and methods of use
|
EP2405758B1
(de)
|
2009-03-09 |
2016-04-27 |
Molecular Express, Inc. |
Verfahren und zusammensetzungen für die liposomale formulierung von antigenen und ihre verwendung
|
ITMI20090946A1
(it)
|
2009-05-28 |
2010-11-29 |
Novartis Ag |
Espressione di proteine ricombinanti
|
EP2442827B1
(de)
|
2009-06-16 |
2016-01-06 |
The Regents of the University of Michigan |
Nanoemulsionsimpfstoffe
|
EP2576791B8
(de)
|
2010-05-23 |
2016-12-21 |
Aduro BioTech, Inc. |
Verfahren und zusammensetzungen mit listeria zur hilfsbehandlung von krebs
|
AU2011262346B2
(en)
|
2010-06-04 |
2014-12-11 |
Wyeth Llc |
Streptococcus pneumoniae vaccine formulations
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
MX350142B
(es)
|
2010-08-23 |
2017-08-28 |
Wyeth Llc * |
Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
|
EP3549601B1
(de)
|
2010-09-10 |
2021-02-24 |
Wyeth LLC |
Non-lipidierten varianten von neisseria meningitidis orf2086 antigene
|
SE535625C2
(sv)
|
2010-10-28 |
2012-10-16 |
Toleranzia Ab |
Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
|
KR101998431B1
(ko)
|
2011-04-26 |
2019-07-09 |
몰레큘라 익스프레스 인코포레이티드 |
리포솜 제제
|
CN107837394A
(zh)
|
2011-06-24 |
2018-03-27 |
埃皮托吉尼西斯有限公司 |
作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
WO2013074696A1
(en)
|
2011-11-14 |
2013-05-23 |
Novartis Ag |
Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
MX359256B
(es)
|
2012-03-09 |
2018-09-19 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas.
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
EP2870238A4
(de)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
Zusammensetzungen und verfahren in zusammenhang mit viralen impfstoffen
|
MX2015000789A
(es)
|
2012-07-19 |
2015-05-07 |
Zoetis Llc |
Composiciones de virus de la gripe bovina.
|
AU2013295770A1
(en)
|
2012-07-27 |
2015-01-29 |
Zoetis Services Llc |
Tick toxin compositions
|
PL3421051T3
(pl)
|
2012-08-16 |
2020-10-05 |
Pfizer Inc. |
Sposoby glikokoniugacji i kompozycje
|
BR112015009229B1
(pt)
|
2012-10-24 |
2021-07-20 |
Platelet Targeted Therapeutics, Llc |
Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
|
KR20140075201A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
EP2964665B1
(de)
|
2013-03-08 |
2018-08-01 |
Pfizer Inc |
Immunogene fusionspolypeptide
|
AU2014234982A1
(en)
|
2013-03-15 |
2015-09-24 |
Zoetis Services Llc |
Cross-protection of bovines against B. trehalosi infection by a multi-valent vaccine
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
CA2928700C
(en)
|
2013-11-01 |
2019-01-15 |
University Of Oslo |
Albumin variants and uses thereof
|
CA2929126C
(en)
|
2013-11-13 |
2020-01-07 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
US11452767B2
(en)
|
2013-11-15 |
2022-09-27 |
Oslo Universitetssykehus Hf |
CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
BR122023022294A2
(pt)
|
2014-01-21 |
2023-12-12 |
Pfizer Inc. |
Uso de uma composição imunogênica que compreende um conjugado imunogênico compreendendo um polissacarídeo capsular isolado de streptococcus pneumoniae do sorotipo 15b
|
KR102099741B1
(ko)
|
2014-01-21 |
2020-04-10 |
화이자 인코포레이티드 |
스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
|
JP2017505792A
(ja)
|
2014-02-14 |
2017-02-23 |
ファイザー・インク |
免疫原性糖タンパク質コンジュゲート
|
JP7158853B2
(ja)
|
2014-10-10 |
2022-10-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
|
CN107249626A
(zh)
|
2015-02-19 |
2017-10-13 |
辉瑞大药厂 |
脑膜炎奈瑟球菌组合物及其方法
|
EP4226936A3
(de)
|
2015-03-05 |
2023-09-27 |
Northwestern University |
Nichtneuroinvasive viren und verwendungen davon
|
WO2016179034A2
(en)
|
2015-05-01 |
2016-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
|
WO2017030901A1
(en)
|
2015-08-14 |
2017-02-23 |
Zoetis Services Llc |
Mycoplasma bovis compositions
|
CN108348593B
(zh)
|
2015-08-31 |
2022-08-16 |
泰克诺瓦克斯股份有限公司 |
基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
|
WO2017123201A1
(en)
|
2016-01-11 |
2017-07-20 |
Zoetis Services Llc |
Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
TN2018000301A1
(en)
|
2016-03-14 |
2020-01-16 |
Univ Oslo |
Engineered immunoglobulins with altered fcrn binding
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
US11033615B2
(en)
|
2016-05-31 |
2021-06-15 |
The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland |
Zika virus vaccine and methods of production
|
WO2017221072A2
(en)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
WO2017220753A1
(en)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3269385A1
(de)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
GB201703529D0
(en)
|
2017-03-06 |
2017-04-19 |
Cambridge Entpr Ltd |
Vaccine composition
|
US10525119B2
(en)
|
2017-03-31 |
2020-01-07 |
Boston Medical Center Corporation |
Methods and compositions using highly conserved pneumococcal surface proteins
|
CN111065417B
(zh)
|
2017-06-23 |
2024-04-19 |
美商艾芬尼维克斯公司 |
免疫原性组合物
|
US12005112B2
(en)
|
2017-09-07 |
2024-06-11 |
University Of Oslo |
Vaccine molecules
|
WO2019048928A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
EP3574915A1
(de)
|
2018-05-29 |
2019-12-04 |
Neovacs |
Immunogenes produkt mit il-4 und/oder il-13 zur behandlung von erkrankungen im zusammenhang mit aberranter il-4- und/oder il-13-expression oder -aktivität
|
WO2021021729A1
(en)
|
2019-07-31 |
2021-02-04 |
Sanofi Pasteur Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
US20230338530A1
(en)
|
2020-01-10 |
2023-10-26 |
Lg Chem, Ltd. |
Composition comprising antigen-presenting cell co-expressing mhc and tumor antigen, and cancer treatment using same
|
WO2021151100A1
(en)
|
2020-01-24 |
2021-07-29 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
IL297244A
(en)
|
2020-04-16 |
2022-12-01 |
Parimmune Sas |
Schistosoma-derived 28-kilodalton gst proteins for the treatment of vasculitis
|
EP3900739A1
(de)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
|
CA3192500A1
(en)
|
2020-09-17 |
2022-03-24 |
Laurent REBER |
Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders
|
US20240156935A1
(en)
|
2021-03-31 |
2024-05-16 |
Vib Vzw |
Vaccine Compositions for Trypanosomatids
|
WO2024069420A2
(en)
|
2022-09-29 |
2024-04-04 |
Pfizer Inc. |
Immunogenic compositions comprising an rsv f protein trimer
|